| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $16,887 | 2 | 100 |
Sells | $0 | 0 | 0 |
| QUAY STEVEN C | President & CEO | 1 | $9,887 | 0 | $0 | $9,887 |
| Remmel H. Lawrence | director | 1 | $7,000 | 0 | $0 | $7,000 |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Over the last 12 months, insiders at Atossa Therapeutics, Inc. have bought $16,887 and sold $0 worth of Atossa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Atossa Therapeutics, Inc. have bought $36,546 and sold $316,167 worth of stock each year.
Highest buying activity among insiders over the last 12 months: QUAY STEVEN C (President & CEO) — $9,887. Remmel H. Lawrence (director) — $7,000.
The last purchase of 11,239 shares for transaction amount of $9,887 was made by QUAY STEVEN C (President & CEO) on 2025‑05‑21.
| 2025-05-21 | QUAY STEVEN C | President & CEO | 11,239 0.0088% | $0.88 | $9,887 | -3.86% | ||
| 2025-03-26 | Remmel H. Lawrence | director | 10,000 0.008% | $0.70 | $7,000 | +19.24% | ||
| 2024-04-10 | Finn Jonathan | director | 25,000 0.0202% | $1.77 | $44,250 | -26.86% | ||
| 2023-11-15 | Sale | WEAVER GREGORY L | Former EVP, CFO, & Director | 50,000 0.0395% | $0.65 | $32,500 | +103.08% | |
| 2023-06-20 | WEAVER GREGORY L | EVP & CFO | 50,000 0.0401% | $0.97 | $48,500 | -1.19% | ||
| 2021-07-02 | Sale | WEAVER GREGORY L | director | 107,497 0.0883% | $5.58 | $599,833 | -69.09% | |
| 2017-11-15 | Guse Kyle | CFO, Gen Counsel and Secretary | 10,000 0.0857% | $0.34 | $3,369 | -23.53% | ||
| 2017-04-17 | Remmel H. Lawrence | director | 2,500 0.0345% | $0.63 | $1,580 | -24.59% | ||
| 2016-04-01 | Remmel H. Lawrence | director | 1,500 0.0044% | $0.33 | $495 | -57.08% | ||
| 2016-03-09 | QUAY STEVEN C | President & CEO | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | ||
| 2016-03-09 | Chen Shu-Chih | 15,000 0.0476% | $0.37 | $5,550 | -59.37% | |||
| 2016-02-16 | QUAY STEVEN C | President & CEO | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | ||
| 2016-02-16 | Chen Shu-Chih | 15,000 0.0459% | $0.53 | $7,950 | -54.55% | |||
| 2016-01-19 | QUAY STEVEN C | President & CEO | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | ||
| 2016-01-19 | Chen Shu-Chih | 50,000 0.1586% | $0.20 | $10,000 | +30.00% | |||
| 2015-06-12 | Remmel H. Lawrence | director | 5,400 0.02% | $1.30 | $7,020 | -62.99% | ||
| 2013-11-21 | WEAVER GREGORY L | director | 20,000 0.1359% | $2.58 | $51,570 | -30.41% | ||
| 2013-10-01 | Sale | QUAY STEVEN C | CEO | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | |
| 2013-10-01 | Sale | Chen Shu-Chih | Chief Scientific Officer | 14,530 0.0922% | $5.66 | $82,211 | -67.88% | |
| 2013-05-15 | CROSS ALEXANDER D | director | 1,000 0.0068% | $5.49 | $5,490 | -55.87% |
| QUAY STEVEN C | President & CEO | 13898 0.0108% | $11,108.67 | 4 | 1 | <0.0001% |
| Remmel H. Lawrence | director | 10257 0.0079% | $8,198.42 | 5 | 0 | <0.0001% |
| Chen Shu-Chih | 4348315 3.3663% | $3.48M | 3 | 1 | <0.0001% | |
| CROSS ALEXANDER D | director | 88866 0.0688% | $71,030.59 | 1 | 0 | |
| Finn Jonathan | director | 25000 0.0194% | $19,982.50 | 1 | 0 | <0.0001% |
| Guse Kyle | CFO, Gen Counsel and Secretary | 10000 0.0077% | $7,993.00 | 1 | 0 | <0.0001% |
| WEAVER GREGORY L | Former EVP, CFO, & Director | 55 0% | $43.96 | 2 | 2 | <0.0001% |
$155,580,641 | 77 | -24.21% | $116.06M | |
$4,898,715 | 46 | 40.75% | $110.93M | |
$7,147,964 | 34 | 24.78% | $112.08M | |
$160,539,875 | 21 | -6.57% | $95.2M | |
$3,331,968 | 17 | -23.79% | $94.05M | |
$7,733,516 | 17 | 73.42% | $103.31M | |
$277,862 | 15 | 59.79% | $98.58M | |
$245,302 | 15 | -4.08% | $96.47M | |
$18,563,605 | 15 | 48.91% | $91.06M | |
$15,799,576 | 12 | -39.52% | $94.72M | |
Atossa Therapeutics, Inc. (ATOS) | $145,194 | 11 | -27.37% | $103.25M |
$135,589,307 | 10 | 32.46% | $100.43M | |
$2,762,881 | 8 | -10.76% | $112.71M | |
$5,524,590 | 7 | 7.40% | $118.77M | |
$99,355,998 | 7 | -65.74% | $112.67M | |
$68,692,148 | 6 | -39.10% | $104.89M | |
$105,079 | 4 | -41.57% | $92.85M | |
$32,289,200 | 3 | -5.46% | $122.26M | |
$16,554 | 2 | 41.65% | $100.02M |
| Increased Positions | 21 | +16.8% | 1M | +6.35% |
| Decreased Positions | 52 | -41.6% | 3M | -15.61% |
| New Positions | 9 | New | 326,822 | New |
| Sold Out Positions | 26 | Sold Out | 1M | Sold Out |
| Total Postitions | 94 | -24.8% | 20M | -9.26% |
| Vanguard Group Inc | $4,723.00 | 4.71% | 6.08M | +245,717 | +4.21% | 2025-09-30 |
| Ameriprise Financial Inc | $2,293.00 | 2.29% | 2.95M | -21,700 | -0.73% | 2025-09-30 |
| Blackrock, Inc. | $1,552.00 | 1.55% | 2M | -150,383 | -7% | 2025-09-30 |
| Millennium Management Llc | $1,297.00 | 1.29% | 1.67M | -378,887 | -18.5% | 2025-09-30 |
| Renaissance Technologies Llc | $1,203.00 | 1.2% | 1.55M | -263,588 | -14.54% | 2025-09-30 |
| Geode Capital Management, Llc | $1,058.00 | 1.06% | 1.36M | +61,903 | +4.76% | 2025-09-30 |
| State Street Corp | $353.00 | 0.35% | 454,495 | -62,076 | -12.02% | 2025-09-30 |
| Gsa Capital Partners Llp | $241.00 | 0.24% | 310,754 | +259,725 | +508.98% | 2025-09-30 |
| Northern Trust Corp | $205.00 | 0.2% | 263,377 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $205.00 | 0.2% | 263,369 | +176,451 | +203.01% | 2025-09-30 |